查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2003220

球虫药市场：按产品类型、剂型、最终用途和分销管道分類的全球市场预测，2026-2032年

Anticoccidial Drugs Market by Product Type, Form, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，球虫药物市场价值将达到 2.5973 亿美元，到 2026 年将成长至 2.7492 亿美元，到 2032 年将达到 3.8799 亿美元，复合年增长率为 5.90%。

主要市场统计数据
基准年 2025 2.5973亿美元
预计年份：2026年 2.7492亿美元
预测年份 2032 3.8799亿美元
复合年增长率 (%) 5.90%

简单介绍球虫疗法在现代畜牧业健康管理的策略重要性。

在集约化畜牧管理系统中，球虫药物在维持消化器官系统健康和生产效率方面仍然发挥核心作用。随着畜牧业集约化程度的提高，针对性化学预防和治疗性介入的作用日益凸显，以应对可能损害生产力、动物福利和饲料转换率的疾病威胁。在此背景下，了解球虫治疗的发展趋势对于兽医团队、饲料生产商、监管机构和相关人员至关重要，他们都在努力平衡疗效、安全性和永续性。

这将带来变革性的变化，重塑整个畜牧业球虫药物的研发、使用模式和合理使用方式。

近年来，科学、监管和市场因素的共同作用正在改变球虫疗法的研发、分销和推广。病原体基因组学和体外药敏试验的进步提高了抗药性的检测和监测能力，从而能够开发更有针对性的产品和製定区域性治疗策略。同时，对动物福利和主导品质标准的要求迫使生产者重新评估预防措施，并优先考虑能够减少饲料中药物添加量的综合疾病管理方法。

分析美国于 2025 年宣布的关税对球虫药物供应链和采购的累积营运和策略影响。

2025年实施的关税措施对整个球虫药物供应链产生了连锁反应，涵盖了供应、生产投入和分销环节。对某些药品活性成分和饲料中间体征收的进口关税增加了依赖国际采购的生产商和饲料厂的接收成本。为此，采购团队正在重新评估其供应商组合，优先考虑替代来源，并加强与契约製造生产商的沟通，以确定可以降低成本的生产週期，从而缓解利润率下降的影响。

透过整合终端用途、分销管道、产品类型和配方选择等方面的关键细分洞察，我们支援有针对性的策略方法。

市场区隔阐明了治疗需求与推广障碍之间的交集。基于最终用途，市场研究涵盖牛、家禽和猪三大领域，其中家禽市场透过不同的生产系统（肉鸡和蛋鸡）进行了更详细的分析。这些物种和系统层面的差异导致了给药时间、给药策略以及与饲料管理技术的整合方面的差异。饲料添加剂配方和饮用水治疗剂在肉鸡生产週期和蛋鸡管理中采用不同的方法，从而对产品开发和行销提出了独特的要求。同一物种内不同治疗类别之间的转换取决于生产规模、生物安全通讯协定以及零售商和加工商的特定要求。

区域洞察聚焦在美洲、欧洲、中东和非洲以及亚太地区的各种因素及其对产品策略的影响。

区域趋势影响着监管重点、疾病压力和采购行为。在美洲，生产规模、一体化供应链和加工商主导的品质管理系统推动了对稳定、与饲料相容的球虫药物的需求。生产商倾向于选择符合高生产率系统和严格食品安全要求的产品。在欧洲、中东和非洲，对某些合成化合物的监管以及对合理使用抗菌剂的高度重视，正促使产品转向兼顾疗效和残留风险的选择。在许多欧洲市场，零售商的倡议和以动物福利主导也在倡议着向综合管理方法的转变，并减少对预防性用药的依赖。

来自主要企业的见解，重点关注策略行动、研发重点领域和合作模式，这些都影响着球虫药市场的竞争趋势。

市场参与企业展现出多元化的策略策略，这反映了它们的规模、产品组合广度和垂直整合程度。大规模跨国动物用药品公司优先考虑製剂稳定性创新、抗药性降低技术以及结合诊断和合理用药方案的综合服务交付。这些企业投资于全球监管合规能力，以应对不同的残留标准和註册要求，并通常采用多通路分销模式，以涵盖工业整合商和小规模独立生产商。中型和区域性生产商则利用接近性饲料厂网路和合约农场丛集的优势，专注于成本竞争力强的製剂、本地监管专业知识和供应链可靠性。

为行业领导者提供实用建议，使其产品开发、商业策略和管理与不断变化的市场现实保持一致。

产业领导者应优先考虑将产品功效、农场实施和抗药性管理相结合的综合方法。投资于诊断和监测方面的伙伴关係将有助于提高治疗性介入的针对性，并支持以数据为导向的作物轮作或合併用药策略，从而维持疗效。同时，提高製剂与常用饲料厂工作流程和液体给药系统的兼容性，可降低推广门槛，提高给药准确性。这些技术投资应与兽医和饲料管理人员的教育计画结合，以确保正确使用并强化管理原则。

调查方法详细介绍了为确保研究结果的可靠性和适用性而采用的资料收集、检验过程和分析方法。

本研究采用混合方法，结合一手访谈、二手文献分析和供应链图谱建构全面的证据基础。一手资料透过对兽医、饲料厂经理、契约製造生产商和分销专家的结构化访谈获得，以了解实际情况和推广应用的障碍。二手资讯则来自关于球虫生物学和治疗效果的同行评审文献、监管通告、产品标籤和公开贸易文件，以支持技术和政策背景。

结论总结了从事球虫领域工作的相关人员面临的策略挑战以及实现永续治疗效果的途径。

球虫药物领域正受到科学进步、监管压力、分销模式转变和贸易趋势的重塑。维持疗效需要整合产品创新和合理用药、稳健的供应链设计以及有针对性的商业性合作等综合策略。成功的企业将致力于使製剂研发与临床实践相契合，投资于抗药性监测伙伴关係，并采用既能扩大患者可及性又能保证品质的分销模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：球虫药市场：依产品类型划分

  • 离子载体
    • 拉萨罗
    • 孟宁素
    • 沙利霉素
  • 合成药物
    • 硝基呋喃
    • 奎诺酮
    • 磺胺类药物药物

第九章：球虫药市场：依剂型划分

  • 饲料添加剂
  • 液体
  • 预混合料

第十章：球虫药市场：依最终用途划分

  • 牛
  • 家禽
    • 肉鸡
    • 产蛋母鸡
  • 猪

第十一章：球虫药市场：依通路划分

  • 在线的
  • 离线

第十二章：球虫药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：球虫药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：球虫药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国球虫药市场

第十六章：中国球虫药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alltech, Inc.
  • BASF SE
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Cargill, Incorporated
  • Ceva Sante Animale
  • DCBL Pharmaceuticals Ltd.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Evonik Industries AG
  • HIPRA SA
  • Huvepharma AD
  • Impextraco NV
  • Intas Pharmaceuticals Limited
  • Kemin Industries, Inc.
  • Lallemand Inc.
  • Merck & Co., Inc.
  • Novus International, Inc.
  • Nutreco NV
  • Phibro Animal Health Corporation
  • Qilu Animal Health Products Co., Ltd.
  • VH Group
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-456C7E8666FE

The Anticoccidial Drugs Market was valued at USD 259.73 million in 2025 and is projected to grow to USD 274.92 million in 2026, with a CAGR of 5.90%, reaching USD 387.99 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 259.73 million
Estimated Year [2026] USD 274.92 million
Forecast Year [2032] USD 387.99 million
CAGR (%) 5.90%

A concise introduction framing the strategic importance of anticoccidial therapies in modern livestock health management

Anticoccidial drugs remain central to maintaining gastrointestinal health and production efficiency across intensively managed livestock systems. As the industry has intensified, the role of targeted chemoprophylaxis and therapeutic interventions has expanded to address disease pressure that would otherwise undermine productivity, animal welfare, and feed conversion outcomes. In this context, understanding the evolving landscape of anticoccidial approaches is essential for veterinary teams, feed manufacturers, regulatory bodies, and commercial stakeholders seeking to balance efficacy, safety, and sustainability.

This report synthesizes recent scientific advances, regulatory movements, distribution channel evolution, and end-use dynamics to provide an integrated view of contemporary anticoccidial practice. It examines how product formulation choices, shifts in species-specific husbandry, and emerging resistance patterns are influencing treatment selection and supply chain decisions. By establishing a clear baseline of current practice and emerging pressures, the analysis supports evidence-based planning for research investment, market entry, and policy engagement.

Throughout the analysis, emphasis is placed on pragmatic implications for decision-makers: how formulation and delivery choices intersect with on-farm workflows, how distribution models affect accessibility and stewardship, and how regulatory and trade developments influence sourcing and manufacturing strategies. The introduction thus frames the subsequent sections that explore transformative shifts, tariff impacts, segmentation insights, regional nuances, competitor behavior, actionable recommendations, methodology, and the overarching conclusions that guide operational and strategic responses.

Transformative shifts reshaping anticoccidial drug development, use patterns, and stewardship across animal agriculture

Recent years have seen a convergence of scientific, regulatory, and market drivers that are transforming how anticoccidial therapies are developed, distributed, and deployed. Advances in pathogen genomics and in vitro susceptibility testing have improved the capacity to detect and monitor resistance, enabling more targeted product development and localized treatment strategies. At the same time, animal welfare imperatives and retailer-driven quality standards are pushing producers to reassess prophylactic approaches and favor integrated disease management practices that reduce blanket medicated feed usage.

Concurrently, the product landscape is evolving. Ionophores continue to be valued for their efficacy and feed-additive compatibility, while synthetic compounds remain critical in therapeutic contexts where resistance or specific lifecycle stages necessitate their use. Formulation innovation-such as improved premixes and stabilized liquids-has increased dosing precision and ease of integration into feed and water systems. Distribution channels are also shifting; direct sales relationships and specialty veterinary channels are strengthening, while digital platforms and online pharmacies expand accessibility and alter purchasing behavior.

Moreover, sustainability and regulatory compliance considerations are driving supply chain reconfiguration. Manufacturers and feed integrators are investing in upstream quality control, traceability, and alternative sourcing to mitigate exposure to trade disruptions and regulatory changes. Taken together, these shifts are recalibrating competitive dynamics, research priorities, and operational practices across the anticoccidial ecosystem, demanding adaptive strategies from pharmaceutical developers, contract manufacturers, feed companies, and veterinary service providers.

Analyzing the cumulative operational and strategic consequences of United States tariffs announced in 2025 on anticoccidial supply chains and procurement

The tariff measures introduced in 2025 have had ripple effects across the supply chains that support anticoccidial drug availability, manufacturing inputs, and distribution economics. Import duties on certain active pharmaceutical ingredients and intermediary feed materials have increased landed costs for manufacturers and feed mills that rely on international sourcing. In response, procurement teams have re-evaluated supplier portfolios, prioritized alternative origins, and escalated conversations with contract manufacturers to identify cost-saving production windows and mitigate margin erosion.

These tariff-driven adjustments have also accelerated nearshoring conversations and investments. Companies with flexible manufacturing footprints have reallocated production or increased inventory buffers to preserve supply continuity. Simultaneously, smaller producers and regional feed integrators have faced more pronounced cost pressures due to limited hedging capabilities, prompting consolidation and strategic partnerships to share scale advantages. Regulatory compliance and customs complexity introduced by tariffs have added administrative overhead, increasing time-to-delivery and influencing ordering cadence.

Importantly, distribution channels have adapted to tariff-induced cost volatility. Direct-sales teams and specialty distributors have intensified value-based conversations with customers, emphasizing formulation benefits and stewardship programs that justify premium pricing. Online pharmacies and digital procurement platforms have helped some buyers source alternative formulations or generics from non-impacted jurisdictions, though quality assurance and regulatory conformity remain primary considerations. Overall, the cumulative impact of tariffs has reshaped sourcing strategies, compelled operational resilience investments, and influenced commercial positioning across the anticoccidial value chain.

Key segmentation insights synthesizing end use, distribution channels, product types, and formulation choices to inform targeted strategic initiatives

Segmenting the market clarifies where therapeutic demand and adoption barriers intersect. Based on end use, the market is studied across cattle, poultry, and swine, with poultry further examined through the distinct production systems of broiler chicken and layer chicken; these species- and system-level differences drive divergent treatment timing, dosing strategies, and integration with feed management practices. Feed additive formulations and in-water therapeutics align differently with broiler cycles versus layer management, creating separate product development and marketing imperatives. Transitioning between therapeutic classes within a species depends on production scale, biosecurity protocols, and retailer or processor specifications.

Considering distribution channel segmentation, the market is studied across direct sales, online pharmacies, and specialty stores, each offering distinct pathways to end users and varying degrees of technical support. Direct sales relationships often support integrated stewardship programs and formalized dosing guidance, while online pharmacies expand access but require robust digital information to preserve correct usage. Specialty stores play a key role in regions with dense independent veterinary practices and feed cooperatives, providing localized advisory services that influence product choice and adherence to recommended protocols.

Product type segmentation clarifies clinical application and resistance management strategies. The market is studied across ionophores and synthetic drugs, with ionophores further studied across lasalocid, monensin, and salinomycin, while synthetic drugs are further studied across nitrofurans, quinolones, and sulfonamides; this taxonomy highlights differing mechanisms of action, regulatory considerations, and therapeutic niches. Ionophores are commonly employed as continuous feed additives in certain production systems, whereas synthetics are more often used for targeted therapeutic courses or in rotation programs. Form-based segmentation reveals how delivery impacts adoption: the market is studied across feed additive, liquid, and premix forms, each providing trade-offs in dosing accuracy, ease of on-farm implementation, and integration with existing feed mill operations. Premix formats support centralized feed production and consistent dosing, feed additives enable continuous prophylaxis at scale, and liquids offer flexible administration in water systems for targeted interventions.

Regional insights highlighting heterogenous drivers across the Americas, Europe, Middle East & Africa, and Asia-Pacific and their implications for product strategy

Regional dynamics shape regulatory priorities, disease pressures, and procurement behavior. In the Americas, production scale, integrated supply chains, and processor-led quality programs create demand for consistent, feed-compatible anticoccidial solutions; producers often favor products that align with high-throughput systems and stringent food-safety requirements. Across Europe, Middle East & Africa, regulatory scrutiny on certain synthetic compounds and strong emphasis on antimicrobial stewardship steer product adoption toward options that balance efficacy and residue risk. Retailer commitments and welfare-driven initiatives in many European markets also influence the transition toward integrated management approaches and reduced prophylactic reliance.

Asia-Pacific presents a mosaic of production systems and regulatory environments that influence both demand and distribution models. High-density poultry production in parts of the region sustains robust demand for accessible, cost-effective anticoccidial programs, while emerging regulatory harmonization efforts are increasing expectations around residue monitoring and quality assurance. Concurrently, digital commerce and evolving veterinary services in parts of Asia-Pacific accelerate adoption of alternative distribution channels. Across regions, localized resistance profiles, feed mill density, and the prevalence of contract farming models combine to determine which product types and forms gain traction, underscoring the need for regionally adapted regulatory strategies and commercial playbooks.

Key company insights emphasizing strategic behaviors, R&D focus areas, and collaborative models shaping competitive dynamics in the anticoccidial space

Market participants exhibit diverse strategic postures that reflect their scale, portfolio breadth, and vertical integration. Large multinational animal health firms prioritize innovation in formulation stability, resistance mitigation technologies, and integrated service offerings that bundle diagnostics and stewardship programs. These organizations invest in global regulatory affairs capabilities to navigate differing residue and registration requirements and often deploy multi-channel distribution models to reach both industrial integrators and smaller independent producers. Mid-sized and regional manufacturers focus on cost-competitive formulations, local regulatory expertise, and supply chain reliability, leveraging proximity to feed mill networks and contract farming clusters.

Across the value chain, contract manufacturing and co-development partnerships have become more common as companies seek to expand capacity without incurring full-scale capital commitments. Collaborative research arrangements between pharmaceutical developers, academic institutions, and diagnostic providers aim to accelerate resistance monitoring tools and refined dosing regimens. Meanwhile, specialized feed additive firms and premix suppliers are differentiating through product customization, technical services, and superior traceability to meet the exacting needs of integrated producers. These company-level behaviors indicate a market where competitive advantage increasingly derives from combined expertise in formulation, regulatory navigation, and on-farm advisory capability rather than solely from molecule ownership.

Actionable recommendations for industry leaders to align product development, commercial strategy, and stewardship with evolving market realities

Industry leaders should prioritize integrated approaches that link product efficacy with on-farm implementation and resistance management. Investing in diagnostics and surveillance partnerships will improve the targeting of therapeutic interventions and support data-driven rotation or combination strategies that preserve efficacy. In parallel, enhancing formulation compatibility with common feed mill workflows and water medication systems will reduce barriers to adoption and improve dosing accuracy. These technical investments should be coupled with educational programs for veterinarians and feed managers to ensure correct use and to reinforce stewardship principles.

On the commercial front, firms should diversify distribution strategies to include strengthened direct-sales capabilities, partnerships with specialty providers, and compliant digital channels that expand reach while maintaining quality assurance. Companies exposed to trade-related cost volatility should evaluate nearshoring options, contractual hedging practices, and supplier diversification to preserve continuity. Finally, leaders must proactively engage regulatory stakeholders and processors on residue monitoring, labeling, and acceptable usage frameworks, because early alignment can de-risk launches and facilitate smoother market access across jurisdictions. Taken together, these measures will help reconcile commercial objectives with the imperative to maintain long-term therapeutic effectiveness.

Research methodology detailing data collection, validation processes, and analytical techniques used to ensure reliability and applicability of findings

The research draws upon a mixed-methods approach combining primary interviews, secondary literature analysis, and supply chain mapping to build a comprehensive evidence base. Primary inputs included structured interviews with veterinarians, feed mill managers, contract manufacturers, and distribution specialists to capture operational realities and adoption barriers. Secondary sources included peer-reviewed literature on coccidiosis biology and treatment efficacy, regulatory filings, product labels, and public trade documentation to corroborate technical and policy contexts.

Data were triangulated to validate trends and reconcile conflicting accounts, with iterative cross-checking between field insights and document-level evidence. Where applicable, regional regulatory databases and customs documentation were consulted to understand tariff impacts and registration constraints. Analytical techniques emphasized qualitative thematic synthesis and comparative regional analysis rather than numerical market sizing, ensuring the report provides actionable strategic intelligence while maintaining methodological transparency. Limitations include variability in reporting standards across jurisdictions and the evolving nature of resistance surveillance data, which the research addresses through conservative interpretation and clear signaling of evidence strength.

Conclusion summarizing the strategic imperatives for stakeholders operating in the anticoccidial domain and the pathways to sustainable therapeutic effectiveness

The anticoccidial landscape is being reshaped by scientific advances, regulatory pressures, shifting distribution models, and trade dynamics. Maintaining therapeutic effectiveness will require integrated strategies that link product innovation with stewardship, robust supply chain design, and targeted commercial engagement. Companies that succeed will be those that align formulation development with on-farm practices, invest in resistance monitoring partnerships, and adopt distribution models that preserve quality while expanding access.

Moving forward, stakeholders should treat resistance management and regulatory alignment as central strategic priorities rather than compliance afterthoughts. By doing so, they will protect efficacy, support animal welfare and food-safety objectives, and create differentiable value propositions for processors and producers. The combined emphasis on diagnostics, formulation compatibility, and adaptive sourcing will define competitiveness in the coming years, enabling sustainable use of anticoccidial interventions across diverse production systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anticoccidial Drugs Market, by Product Type

  • 8.1. Ionophores
    • 8.1.1. Lasalocid
    • 8.1.2. Monensin
    • 8.1.3. Salinomycin
  • 8.2. Synthetic Drugs
    • 8.2.1. Nitrofurans
    • 8.2.2. Quinolones
    • 8.2.3. Sulfonamides

9. Anticoccidial Drugs Market, by Form

  • 9.1. Feed Additive
  • 9.2. Liquid
  • 9.3. Premix

10. Anticoccidial Drugs Market, by End Use

  • 10.1. Cattle
  • 10.2. Poultry
    • 10.2.1. Broiler Chicken
    • 10.2.2. Layer Chicken
  • 10.3. Swine

11. Anticoccidial Drugs Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Anticoccidial Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anticoccidial Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anticoccidial Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anticoccidial Drugs Market

16. China Anticoccidial Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alltech, Inc.
  • 17.6. BASF SE
  • 17.7. Bayer Aktiengesellschaft
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Cargill, Incorporated
  • 17.10. Ceva Sante Animale
  • 17.11. DCBL Pharmaceuticals Ltd.
  • 17.12. Dechra Pharmaceuticals PLC
  • 17.13. Elanco Animal Health Incorporated
  • 17.14. Evonik Industries AG
  • 17.15. HIPRA S.A.
  • 17.16. Huvepharma AD
  • 17.17. Impextraco NV
  • 17.18. Intas Pharmaceuticals Limited
  • 17.19. Kemin Industries, Inc.
  • 17.20. Lallemand Inc.
  • 17.21. Merck & Co., Inc.
  • 17.22. Novus International, Inc.
  • 17.23. Nutreco N.V.
  • 17.24. Phibro Animal Health Corporation
  • 17.25. Qilu Animal Health Products Co., Ltd.
  • 17.26. V H Group
  • 17.27. Vetoquinol S.A.
  • 17.28. Virbac S.A.
  • 17.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTICOCCIDIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTICOCCIDIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LASALOCID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LASALOCID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LASALOCID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY MONENSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY MONENSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY MONENSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SALINOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SALINOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SALINOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY NITROFURANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY NITROFURANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY NITROFURANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FEED ADDITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FEED ADDITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FEED ADDITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PREMIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PREMIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY BROILER CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY BROILER CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY BROILER CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LAYER CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LAYER CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LAYER CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)